Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes

British Journal of Pharmacology

Volumn 154, Issue 5, 2008, Pages 1079-1093

  Liang, Y ^a   Woodward, D F ^a   Guzman, V M ^a   Li, C ^a   Scott, D F ^b   Wang, J W ^a   Wheeler, L A ^a   Garst, M E ^a   Landsverk, K ^c   Sachs, G ^b   Krauss, A H P ^e   Cornell, C ^d   Martos, J ^d   Pettit, S ^d   Fliri, H ^d  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c 206 Carnegie Center   (United States)

^d Selcia Ltd   (United Kingdom)

^e PFIZER INC   (United States)

Author keywords

Calcium signalling; Intraocular pressure; Prostaglandin; Prostamide; Receptor dimerization

Indexed keywords

2,3 (5 FLUORO 2 PROPYLCARBAMOYLMETHOXYBENZYL) 7 OXABICYCLO[2.2.1]HEPT 2 YLOXAZOLE 4 CARBOXYLIC ACID (4 CYCLOHEXYLBUTYL)AMIDE; AGN 211335; BIMATOPROST; CYSTEINE RICH PROTEIN 61; MYOSIN LIGHT CHAIN; PROSTAGLANDIN F RECEPTOR; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT;

ANIMAL TISSUE; ARTICLE; CALCIUM MOBILIZATION; COMPLEX FORMATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; FLUOROMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; NONHUMAN; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; STEADY STATE; UPREGULATION; WESTERN BLOTTING;

ALTERNATIVE SPLICING; AMIDES; AMINO ACID SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; CALCIUM; CELL LINE; CLOPROSTENOL; DIMERIZATION; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KINETICS; MOLECULAR SEQUENCE DATA; MYOSIN LIGHT CHAINS; PHOSPHORYLATION; RECEPTORS, PROSTAGLANDIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; VARIATION (GENETICS);

EID: 46249085441     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.142     Document Type: Article

References (39)

1. Adams JW, Migita DS, Yu MK, Young R, Hellickson MS, Castro-Vargus FE et al. (1996). Prostaglandin F2 alpha stimulates hypertrophic growth of cultured neonatal rat ventricular myocytes. J Biol Chem 271: 1179-1186.
2. Ansari HR, Davis AM, Kaddour-Djebbar I, Abdel-Latif AA (2003). Effects of prostaglandin F2alpha and latanoprost on phosphoinositide turnover, myosin light chain phosphorylation and contraction in cat iris sphincter. J Ocul Pharmacol Ther 19: 217-231.
3. Arunlakshana O, Schild HO (1959). Some quantitative use of drug antagonists. Br J Pharmacol Chemother 257: 48-58.
4. 2 cannabinoid receptors in rat brain and human tonsils. Adv Exp Med Biol 469: 527-533.
5. Breitweiser GA (2004). G protein-coupled receptor oligomerization: implications for G protein activation and cell signaling. Circ Res 94: 17-27.
6. Bulenger S, Marullo S, Bouvier M (2005). Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 26: 131-137.
7. Burstein SH, Rossetti RG, Yagen B, Zurier RB (2000). Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61: 29-41.
8. Crowston JG, Lindsey JD, Morris CA, Wheeler L, Medeiros FA, Weinreb RN (2005). Effect of bimatoprost on intraocular pressure in prostaglandin FP receptor knockout mice. Invest Ophthalmol Vis Sci 46: 4571-4577.
9. Fujino H, Srinivasan D, Pierce KL, Regan JW (2000). Differential regulation of prostaglandin F(2alpha) receptor isoforms by protein kinase C. Mol Pharmacol 57: 353-358.
10. Gagliuso DJ, Wang RF, Mittag TW, Podos SM (2004). Additivity of bimatoprost or travoprost to latanoprost in glaucomatous monkey eyes. Arch Ophthalmol 122: 1342-1347.
11. Gandolfi SA, Cimino L (2003). Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmol 110: 609-614.
12. Gaton DD, Sagart T, Lindsey JD, Gabelt BAT, Kaufman PL, Weinreb RN (2001). Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F(2alpha)-isopropyl ester treatment. Arch Ophthalmol 119: 1165-1170.
13. Horton EW, Poyser NL (1976). Uterine luteolytic hormone: a physiological role for prostaglandin F2alpha. Physiol Rev 56: 595-651.
14. Jordan BA, Devi LA (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700.
15. Koda N, Tsutsui Y, Niwa H, Ito S, Woodward DF, Waternabe K (2003). Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of bimatoprost as a potent unhibitor of the enzyme: new enzyme method by LC/GSI/MS. Arch Biochem Biophys 424: 128-136.
16. Kolodziej PA, Young RA (1991). Epitope tagging and protein surveillance. Methods Enzymol 194: 508-519.
17. Kozak KR, Crews BC, Ray JL, Tai HH, Morrow JD, Marnett LJ (2001). Metabolism of prostaglandin glyceryl esters and prostaglandin ethanolamides in vitro and in vivo. J Biol Chem 276: 36993-36998.
18. Liang Y, Li C, Guzman VM, Evinger III AJ, Protzman CE, Krauss A-H et al. (2003). Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem 278: 27267-27277.
19. Matias I, Chen J, Petrocellis LD, Bisognot T, Ligresti A, Fezza F et al. (2004). Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. J Pharmacol Exp Ther 309: 745-757.
20. McGraw DW, Mihlbachler KA, Schwarb MR, Rahman FR, Small KM, Almoosa KF et al. (2006). Airway smooth muscle prostaglandin-EP1 receptors directly modulate beta2-adrenergic receptors within a unique heterodimeric complex. J Clin Invest 116: 1400-1409.
21. Okuda-Ashitaka E, Sakamoto K, Ezashi KM, Ito S, Hayaishi O (1996). Suppression of prostaglandin E receptor signaling by the variant form of EP1 subtype. J Biol Chem 271: 31255-31261.
22. Ota T, Aihara M, Narumiya S, Araie M (2005). The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 46: 4159-4163.
23. Prinster SC, Hauge C, Hall RA (2005). Heterodimerization of g protein-coupled receptors: specificity and functional significance. Pharmacol Rev 57: 289-298.
24. Resul B, Stjernschantz J, Selen G, Bito L (1997). Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 41: 47-52.
25. Richter M, Krauss AH, Woodward DF, Lutjen-Drecoll E (2003). Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 44: 4419-4426.
26. Ross RA, Craib SJ, Stevenson LA, Pertwee RG, Henderson A, Toole J et al. (2002). Pharmacological characterization of the anandamide cyclooxygenase metabolite: prostaglandin E2 ethanolamide. J Pharmacol Exp Ther 301: 900-907.
27. Sakurai M, Higashide T, Takahashi M, Sugiyama K (2007). Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmol 114: 1039-1046.
28. Smith WL, Marnett LJ, Dewitt DL (1991). Prostaglandin and thromboxane biosynthesis. Pharmacol Ther 49: 153-179.
29. Spada CS, Krauss AH, Woodward DF, Chen J, Protzman CE, Nieves AL et al. (2005). Bimatoprost and prostaglandin F(2 alpha) selectively stimulate intracellular calcium signaling in different cat iris sphincter cells. Exp Eye Res 80: 135-145.
30. Toh H, Ichikawa A, Narumiya S (1995). Molecular evolution of receptors for eicosanoids. FEBS Lett 361: 17-21.
31. Vielhauer GA, Fujino H, Regan JW (2004). Cloning and localization of hFP(S): a six-transmembrane mRNA splice variant of the human FP prostanoid receptor. Arch Biochem Biophys 421: 175-185.
32. Wan Z, Woodward DF, Cornell C, Fliri H, Martos J, Pettit S et al. (2007). Bimatoprost, prostamide activity, and conventional drainage. Invest Ophthalmol Vis Sci 48: 4107-4115.
33. Weinreb RN, Lindsey JD (2002). Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43: 716-722.
34. Wilson SJ, Roche AM, Kostetskaia E, Smyth EM (2004). Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptor-mediated cAMP generation. J Biol Chem 279: 53036-53047.
35. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM et al. (2001). The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 45: S337-S345.
36. Woodward DF, Krauss AHP, Chen J, Liang Y, Li C, Protzman E et al. (2003). Pharmacological characterization of a novel antiglaucoma agent, Bimatoprost (AGN 192024). J Pharmacol Exp Ther 305: 772-785.
37. Woodward DF, Krauss AHP, Wang JW, Protzman CE, Nieves AL, Liang Y et al. (2007). Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin- ethanolamides) in the feline iris. Br J Pharmacol 150: 342-352.
38. Woodward DF, Lawrence RA, Fairbairn CE, Shan T, Williams LS (1993). Intraocular pressure effects of selective prostanoid receptor agonists involve different receptor subtypes according to radioligand binding studies. J Lipid Mediat 6: 545-553.
39. Yu M, Ives D, Ramesh CS (1997). Synthesis of prostaglandin E2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272: 21181-21186.